| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
82,823,000 |
| Market
Cap: |
1.72(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$18.92 - $29.92 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 484 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Veracyte is a genomic diagnostics company. Co. develops tests that address clinical needs in the diagnosis, prognosis and treatment of cancer and other diseases. Co. provides tests in: thyroid cancer via its Afirma Genomic Sequencing Classifier (GSC) and Xpression Atlas; prostate cancer via its Decipher Biopsy and Radical Prostatectomy Genomic Classifiers; breast cancer via its Prosigna Breast Cancer Assay; lung cancer via its Percepta GSC and Percepta Nasal Swab Test; interstitial lung diseases including idiopathic pulmonary fibrosis via its Envisia Genomic Classifier; bladder cancer via its Decipher Bladder Genomic Classifier; and colon cancer via its Immunoscore Colon Cancer Test.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
60,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$980,094 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
11,539 |
21,539 |
104,169 |
536,685 |
| Total Sell Value |
$248,847 |
$492,446 |
$2,960,641 |
$14,057,583 |
| Total People Sold |
2 |
3 |
4 |
8 |
| Total Sell Transactions |
2 |
3 |
12 |
31 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kennedy Keith |
COO / CFO |
• – – |
2020-02-24 |
4 |
D |
$0.00 |
$0 |
D/D |
(13,163) |
147,400 |
|
- |
|
| Kennedy Keith |
COO / CFO |
• – – |
2020-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
160,563 |
|
- |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2020-01-10 |
4 |
AS |
$28.86 |
$577,276 |
D/D |
(20,000) |
117,738 |
|
-14% |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2020-01-10 |
4 |
OE |
$4.00 |
$80,000 |
D/D |
20,000 |
137,738 |
|
- |
|
| Kennedy Keith |
COO / CFO |
• – – |
2019-12-27 |
4 |
AS |
$30.00 |
$12,002 |
D/D |
(400) |
109,703 |
|
- |
|
| Kennedy Keith |
COO / CFO |
• – – |
2019-12-27 |
4 |
OE |
$7.47 |
$2,988 |
D/D |
400 |
110,103 |
|
- |
|
| Jones Evan/ Fa |
Director |
– • – |
2019-12-17 |
4 |
AS |
$29.26 |
$438,866 |
I/I |
(15,000) |
158,702 |
|
- |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2019-12-10 |
4 |
OE |
$2.68 |
$120,200 |
D/D |
35,000 |
117,738 |
|
- |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2019-12-10 |
4 |
AS |
$28.96 |
$579,248 |
D/D |
(20,000) |
102,738 |
|
- |
|
| Hanna John Walter Jr |
Chief Commercial Officer |
• – – |
2019-12-06 |
4 |
AS |
$30.09 |
$295,995 |
D/D |
(9,838) |
65,275 |
|
- |
|
| Hanna John Walter Jr |
Chief Commercial Officer |
• – – |
2019-12-06 |
4 |
OE |
$9.05 |
$89,034 |
D/D |
9,838 |
75,113 |
|
- |
|
| Kennedy Keith |
COO / CFO |
• – – |
2019-12-06 |
4 |
AS |
$30.04 |
$416,146 |
D/D |
(13,851) |
109,703 |
|
- |
|
| Kennedy Keith |
COO / CFO |
• – – |
2019-12-06 |
4 |
OE |
$7.47 |
$103,467 |
D/D |
13,851 |
123,554 |
|
- |
|
| Jones Evan/ Fa |
Director |
– • – |
2019-12-06 |
4 |
AS |
$30.03 |
$24,022 |
I/I |
(800) |
173,702 |
|
- |
|
| Hanna John Walter Jr |
Chief Commercial Officer |
• – – |
2019-12-05 |
4 |
AS |
$30.01 |
$243,047 |
D/D |
(8,100) |
65,275 |
|
- |
|
| Hanna John Walter Jr |
Chief Commercial Officer |
• – – |
2019-12-05 |
4 |
OE |
$9.05 |
$73,305 |
D/D |
8,100 |
73,375 |
|
- |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2019-12-05 |
4 |
AS |
$29.39 |
$964,142 |
D/D |
(32,803) |
46,862 |
|
- |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2019-12-05 |
4 |
OE |
$14.34 |
$470,395 |
D/D |
32,803 |
79,665 |
|
- |
|
| Kennedy Keith |
COO / CFO |
• – – |
2019-12-05 |
4 |
AS |
$30.00 |
$579,069 |
D/D |
(19,300) |
109,703 |
|
- |
|
| Kennedy Keith |
COO / CFO |
• – – |
2019-12-05 |
4 |
OE |
$5.98 |
$133,208 |
D/D |
19,300 |
129,003 |
|
- |
|
| Jones Evan/ Fa |
Director |
– • – |
2019-12-05 |
4 |
AS |
$30.00 |
$154,535 |
I/I |
(5,151) |
174,502 |
|
- |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2019-12-03 |
4 |
AS |
$26.47 |
$405,663 |
D/D |
(15,327) |
46,862 |
|
- |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2019-12-03 |
4 |
OE |
$5.43 |
$107,103 |
D/D |
15,032 |
62,189 |
|
- |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2019-12-02 |
4 |
D |
$27.19 |
$26,864 |
D/D |
(988) |
102,738 |
|
- |
|
| Hanna John Walter Jr |
Chief Commercial Officer |
• – – |
2019-12-02 |
4 |
D |
$27.19 |
$5,900 |
D/D |
(217) |
65,275 |
|
- |
|
524 Records found
|
|
Page 13 of 21 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.24 (1.14%) 
